Nasdaq · CIK 0001826457
GLUE Monte Rosa Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 6 d ago. Close $10.30 on Oct 9, 2026, +22% from the 52-week low and -59% from the high.
Last 90 days
Net insider value
-$137
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$137 by 1 insider
Insiders on file
12
with a Form 4 at this company
Price and insider trades, last year
GLUEOct 9, 2026 · close 10.30
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Monte Rosa Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Matthew Bowen Principal Accounting Officer sell | $137 13 shares | -0% | +39% from low-59% from high | |
| 15Weak | Edmund Dunn Principal Accounting Officer sell | $9,174 2,062 shares | -8% | +25% from low-55% from high | |
| 37Weak | Versant Venture Capital VI, L.P. owner sell | $1.5M 157,895 shares | -8% | - |
Transactions
The last 29 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Matthew Bowen Principal Accounting Officer | SOpen-market sale Common Stock | -13 | $10.56 | $137 | 25,891 | 6 d ago |
| Jun 13, 2025 | Ali Behbahani director, owner | AGrant or award Stock Option (Right to Buy)derivative | +30,700 | $0.00 | $0 | 30,700 | Jun 16, 2025 |
| Jun 13, 2025 | Kimberly Blackwell director | AGrant or award Stock Option (Right to Buy)derivative | +30,700 | $0.00 | $0 | 30,700 | Jun 16, 2025 |
| Jun 13, 2025 | Eric A Hughes director | AGrant or award Stock Option (Right to Buy)derivative | +30,700 | $0.00 | $0 | 30,700 | Jun 16, 2025 |
| Jun 13, 2025 | Anthony M. Manning director | AGrant or award Stock Option (Right to Buy)derivative | +30,700 | $0.00 | $0 | 30,700 | Jun 16, 2025 |
| Jun 13, 2025 | Andrew N Schiff director | AGrant or award Stock Option (Right to Buy)derivative | +30,700 | $0.00 | $0 | 30,700 | Jun 16, 2025 |
| Jun 13, 2025 | Jan Skvarka director | AGrant or award Stock Option (Right to Buy)derivative | +30,700 | $0.00 | $0 | 30,700 | Jun 16, 2025 |
| Jun 13, 2025 | Christine Siu director | AGrant or award Stock Option (Right to Buy)derivative | +30,700 | $0.00 | $0 | 30,700 | Jun 16, 2025 |
| Jun 3, 2025 | Edmund Dunn Principal Accounting Officer | SOpen-market sale Common Stock | -2,062 | $4.45 | $9,174 | 23,732 | Jun 4, 2025 |
| Jan 2, 2025 | Jennifer Champoux Chief Operating Officer | AGrant or award Common Stock | +30,000 | - | - | 30,000 | Jan 6, 2025 |
| Jan 2, 2025 | Edmund Dunn Principal Accounting Officer | AGrant or award Common Stock | +11,850 | - | - | 25,794 | Jan 6, 2025 |
| Jan 2, 2025 | Filip Janku Chief Medical Officer | AGrant or award Common Stock | +36,000 | - | - | 45,189 | Jan 6, 2025 |
| Jan 2, 2025 | Filip Janku Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +161,000 | $0.00 | $0 | 161,000 | Jan 6, 2025 |
| Jan 2, 2025 | Edmund Dunn Principal Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +53,400 | $0.00 | $0 | 53,400 | Jan 6, 2025 |
| Jan 2, 2025 | Jennifer Champoux Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +135,000 | $0.00 | $0 | 135,000 | Jan 6, 2025 |
| Dec 11, 2024 | Eric A Hughes director | AGrant or award Stock Option (Right to Buy)derivative | +44,200 | $0.00 | $0 | 44,200 | Dec 13, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | SOpen-market sale Common Stockindirect: See Footnote | -89,990 | $9.66 | $869k | 2,007,948 | Oct 30, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | JOther Common Stock | -1,019,867 | $0.00 | $0 | 4,079,469 | Oct 30, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | JOther Common Stockindirect: See Footnote | +20,397 | $0.00 | $0 | 20,397 | Oct 30, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | JOther Common Stockindirect: See Footnote | -20,397 | $0.00 | $0 | 0 | Oct 30, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | JOther Common Stockindirect: See Footnote | +17,595 | $0.00 | $0 | 17,595 | Oct 30, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | JOther Common Stockindirect: See Footnote | -17,595 | $0.00 | $0 | 0 | Oct 30, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | JOther Common Stockindirect: See Footnote | -366,590 | $0.00 | $0 | 1,641,358 | Oct 30, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | JOther Common Stockindirect: See Footnote | +5,499 | $0.00 | $0 | 5,499 | Oct 30, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | JOther Common Stockindirect: See Footnote | -5,499 | $0.00 | $0 | 0 | Oct 30, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | JOther Common Stockindirect: See Footnote | +5,454 | $0.00 | $0 | 5,454 | Oct 30, 2024 |
| Oct 28, 2024 | Versant Venture Capital VI, L.P. owner | JOther Common Stockindirect: See Footnote | -5,454 | $0.00 | $0 | 0 | Oct 30, 2024 |
| Oct 29, 2024 | Versant Venture Capital VI, L.P. owner | SOpen-market sale Common Stockindirect: See Footnote | -52,305 | $9.08 | $475k | 1,589,053 | Oct 30, 2024 |
| Oct 29, 2024 | Versant Venture Capital VI, L.P. owner | SOpen-market sale Common Stockindirect: See Footnote | -15,600 | $9.41 | $147k | 1,573,453 | Oct 30, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Ali Behbahaniowner, director
- Kimberly Blackwelldirector
- Matthew BowenPrincipal Accounting Officer
- Jennifer ChampouxChief Operating Officer
- Edmund DunnPrincipal Accounting Officer
- Eric A Hughesdirector, officer
- Filip JankuChief Medical Officer
- Anthony M. Manningdirector
- Andrew N Schiffdirector
- Christine Siudirector
- Jan Skvarkadirector
- Versant Venture Capital VI, L.P.owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.